A New Molecular Entity (NME) is a drug substance containing an active moiety that has not previously been approved for marketing in a given jurisdiction.
NME designation signals a novel compound with limited human exposure history, requiring robust nonclinical and early-phase safety evaluation. Clinical development programs for NMEs typically include cautious dose escalation and intensive pharmacokinetic and pharmacodynamic monitoring. Regulatory review of NMEs focuses heavily on benefitñrisk balance and safety characterization. Thorough documentation and high-quality trial data are essential to support approval decisions for NMEs.